Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

GENE - CHEMICAL INTERACTIONS REPORT

RGD ID: 1560889
Species: Rattus norvegicus
RGD Object: Gene
Symbol: Ces2h
Name: carboxylesterase 2H
Acc ID: CHEBI:80630
Term: irinotecan
Definition: A member of the class of pyranoindolizinoquinolines that is the carbamate ester obtained by formal condensation of the carboxy group of [1,4'-bipiperidine]-1'-carboxylic acid with the phenolic hydroxy group of (4S)-4,11-diethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2- hydrochloride]quinoline-3,14-dione. Used (in the form of its hydrochloride salt trihydrate) in combination with fluorouracil and leucovorin, for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. It is converted via hydrolysis of the carbamate linkage to its active metabolite, SN-38, which is ~1000 times more active.
Chemical ID: MESH:D000077146
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction is comprised of a complex set of reactions and/or regulatory events, possibly involving additional chemicals and/or gene products.
Object SymbolQualifierEvidenceWithReferenceSourceNotesOriginal Reference(s)
Ces2haffects response to substanceISOCES2 (Homo sapiens)6480464CTDCES2 protein affects the susceptibility to IrinotecanPMID:16963839
Ces2hincreases chemical synthesisISOCES2 (Homo sapiens)6480464CTDCES2 protein results in increased chemical synthesis of IrinotecanPMID:11716702 PMID:12171891 PMID:15592324 PMID:16203781
Ces2hincreases expressionISOCES2 (Homo sapiens)6480464CTDIrinotecan results in increased expression of CES2 mRNAPMID:16963839
Ces2hincreases hydrolysisISOCES2 (Homo sapiens)6480464CTDCES2 protein results in increased hydrolysis of IrinotecanPMID:14581373 PMID:15100172 PMID:15475733
Ces2hincreases metabolic processingISOCES2 (Homo sapiens)6480464CTDCES2 protein results in increased metabolism of IrinotecanPMID:16203781
Ces2hincreases response to substanceISOCES2 (Homo sapiens)6480464CTDCES2 protein results in increased susceptibility to IrinotecanPMID:15655543
Ces2hmultiple interactionsISOCES2 (Homo sapiens)6480464CTDCES2 mRNA results in increased chemical synthesis of and results in increased abundance of Irinotecan; CES2 mRNA results in increased metabolism of and results in increased activity of Irinotecan; CES2 protein affects the metabolism of and results in increased activity of Irinotecan; CES2 protein results in increased hydrolysis of and results in increased activity of Irinotecan; CES2 protein results in increased metabolism of and results in increased activity of IrinotecanPMID:10728672 PMID:11716702 PMID:12171891 PMID:12171903 PMID:15592324 PMID:15655543 PMID:16203781
Go Back to source page   Continue to Ontology report